Swiss pharmaceutical major Roche (SWX: ROG), through its subsidiary Genentech, has released a statement addressing an accidental disclosure of the second interim analysis from an ongoing Phase III study. The study involves the anti-TIGIT biologic tiragolumab, used with and without the PD-L1 inhibitor Tecentriq (atezolizumab), for patients with PD-L1-high locally advanced or metastatic non-small cell lung cancer (NSCLC).
Data Maturity and Trial Continuation
Genentech clarified that at the time of the data cut-off, with a median follow-up of 15.5 months, the data for the primary endpoint of overall survival (OS) was not mature. Despite this premature disclosure, the company highlighted that the combination therapy has demonstrated good tolerance among participants. The trial is set to continue until the final OS readout is available, ensuring a comprehensive evaluation of the treatment’s efficacy and safety.
No Impact on Other Tiragolumab Studies
The accidental disclosure has not affected any other studies involving tiragolumab, maintaining the integrity and progress of the broader research program. Genentech’s swift response and clarification aim to preserve the scientific rigor of the trial and provide confidence in the ongoing evaluation of tiragolumab’s potential as a treatment for NSCLC.-Fineline Info & Tech
